Literature DB >> 168905

Retardation of colony growth of in vitro bone marrow culture using sera from patients with Felty's syndrome, disseminated lupus erythematosus (SLE), rheumatoid arthritis, and other disease states.

D J Duckham, R L Rhyne, F E Smith, R C Williams.   

Abstract

Whole sera and serum fractions from 24 patients with Felty's syndrome, 42 patients with systemic lupus erythematosus (SLE), and 48 patients with rheumatoid arthritis (RA), as well as 30 patients with miscellaneous acute and chronic disease states, were studied for their effect on numbers of mouse bone marrow colonies grown on soft agar in the presence of human colony stimulating factor. Significant early retardation of mouse bone marrow colony counts was recorded in 87.5 percent of Felty's sera, 43 percent of SLE sera, and 12.5 percent of sera from patients with uncomplicated RA. Forty percent of 30 other control patients with acute or chronic inflammatory diseases also showed this activity. No diminution was noted with any of 40 normal control sera. Degree of marrow colony retardation could be directly correlated to amounts of test serum added. No single serum fraction isolated by ion exchange chromatography, gel filtration, or electrophoresis was identified as solely responsible for marrow growth retardation; however lipoprotein fractions including chylomicrons, LDL and HDL showed inhibiting activity in various sera.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 168905     DOI: 10.1002/art.1780180405

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  Suppressor cell-mediated neutropenia in Felty's syndrome.

Authors:  N I Abdou; C NaPombejara; L Balentine; N L Abdou
Journal:  J Clin Invest       Date:  1978-03       Impact factor: 14.808

2.  Correlation of disease activity and Clq-binding immune complexes with the neutrophil inclusions which form in the presence of SLE sera.

Authors:  E R Hurd; H E Jasin; J N Gilliam
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

3.  Heterogeneous neurocytotoxic antibodies in systemic lupus erythematosus.

Authors:  H G Bluestein
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

4.  Circulating colony-forming units of granulocytes and monocytes/macrophages in systemic lupus erythematosus.

Authors:  X López-Karpovitch; M Cardiel; R Cardenas; J Piedras; D Alarcón-Segovia
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

5.  Humoral and cellular immune mechanisms of neutropenia in patients with Felty's syndrome.

Authors:  G Starkebaum; J W Singer; W P Arend
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

Review 6.  Haematological manifestations of lupus.

Authors:  Anum Fayyaz; Ann Igoe; Biji T Kurien; Debashish Danda; Judith A James; Haraldine A Stafford; R Hal Scofield
Journal:  Lupus Sci Med       Date:  2015-03-03

7.  Targeted Therapy with Rituximab in Felty's Syndrome: A Case Report.

Authors:  Line Heylen; Daan Dierickx; Peter Vandenberghe; René Westhovens
Journal:  Open Rheumatol J       Date:  2012-11-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.